Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 12, 2020
- Accepted in final form November 4, 2020
- First Published January 6, 2021.
Author Disclosures
- Veit Rothhammer, MD (veit.rothhammer{at}tum.de),
- Jessica E. Kenison, MSc (jessica.kenison{at}antolrx.com),
- Zahorong Li, MSc (zli37{at}bwh.harvard.edu),
- Emily Tjon, MSc (emilyctjon{at}gmail.com),
- Maisa C. Takenaka, PhD (mcstakenaka{at}gmail.com),
- Chun-Cheih Chao, PhD (u911636{at}gmail.com),
- Kalil Alves de Lima, PhD (kalil.delima{at}gmail.com),
- Davis M. Borucki, MSc (boruckid{at}musc.edu),
- Joel Kaye, PhD (joel.k{at}ayalapharma.com) and
- Francisco J. Quintana, PhD
- Veit Rothhammer, MD (veit.rothhammer{at}tum.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Novartis Pharmaceuticals, Research Support
German Research Foundation, RO4866, PI, 2018 - 2023 European Research Council, HICI, 2020 - 2024
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jessica E. Kenison, MSc (jessica.kenison{at}antolrx.com),
NONE
NONE
(1) AnTolRx, Inc. Funding for travel to conferences
NONE
NONE
NONE
NONE
(1) AnTolRx, Inc.
NONE
NONE
NONE
(1) AnTolRx, Inc.
NONE
(1) Boston University
NONE
NONE
NONE
NONE
(1) AnTolRx, Inc. (2016-present)
NONE
NONE
- Zahorong Li, MSc (zli37{at}bwh.harvard.edu),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Emily Tjon, MSc (emilyctjon{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maisa C. Takenaka, PhD (mcstakenaka{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Chun-Cheih Chao, PhD (u911636{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kalil Alves de Lima, PhD (kalil.delima{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Davis M. Borucki, MSc (boruckid{at}musc.edu),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Joel Kaye, PhD (joel.k{at}ayalapharma.com) and
NONE
NONE
NONE
NONE
Patents regarding Laquinimod: Patent US 8,598,203: Treatment of CrohnÂs Disease with Laquinimod. Patent US 8,501,766: Treatment of Rheumatoid Arthritis with a Combination of Laquinimod and Methotrexate. Patent US 9,161,935: Use of Laquinimod for treating CrohnÂs Disease patients who failed first-line anti-TNF therapy. Patent US 9,359,606: Anti-Clusterin Monotherapy for Cancer Treatment. 20130203807: Treatment of Ocular Inflammatory Diseases with Laquinimod. 20130259856: Treatment of Multiple Sclerosis with Combination of Laquinimod and Dimethyl Fumarate. 20130096158: Treatment of Multiple Sclerosis with Combination of Laquinimod and Fingolimid. 20140017226: Treatment of Multiple Sclerosis with Combination of Laquinimod and Fampridine. 20150094332: Laquinimod Combination Therapy For Treatment Of Multiple Sclerosis.
NONE
Currently employed by Ayala Pharmaceuticals (From December 2018) Previously employed by Teva Pharmaceutical Industries directly related to this manuscript
NONE
NONE
NONE
NONE
1) Salary from Teva Pharmaceuticals
NONE
NONE
NONE
NONE
NONE
NONE
I held stock options from Teva Pharmaceuticals, but once I left they were no longer available to me
NONE
NONE
- Francisco J. Quintana, PhD
NONE
NONE
NONE
2012 Editorial Board Member Systems Biomedicine 2012 Editorial Board Member Inmunologia (Spain) 2013- Associate Editor Immunology (UK) 2013- Senior Editorial Board Member American Journal of Clinical and Experimental Immunology 2014- Advisory Board MemberSeminars in Immunopathology
NONE
NONE
NONE
Teva, Blueprint Medicines, AnTolRx
NONE
NONE
NONE
1. EMD-Serono 2. Sanofi 3. Novartis 4. Teva 5. ONO
(1) NIH, R00 AI075285-01A2, Role PI, 2010-2012, (2) NIH, R01 AI093903-01, Role PI, 2011Â2016, (3) NIH, K99AI075285-01A2, Role PI, 2009-2010, (4) NIH, 1R01NS102807-01A1, role PI, 09/01/18 Â 08/31/23, (5) NIH, R01 ES025530-02, role PI, 06/01/16 Â 05/31/21, (6) NMSS, JF 2161-A-5, role PI, 07/01/14 Â 06/30/19, (7) American Cancer Soc., 126566-RSG-14-198-01-LIB, role PI, 01/01/15 Â 12/31/18, (8) NMSS, RR-1601-07385, role PI, 10/01/16 Â 09/30/19, (9) Israel Cancer Research Fund, 15-975-ICG, role PI, 09/01/16 Â 08/30/19, (10) NIH-NIAID, 1R01AI126880-01A1, role PI, 02/01/17 Â 01/31/22, (11) NIH-NIAID, 2R01HL095722-06A1, role PI, 09/01/15 Â 08/31/20, (12) NMSS, PA-1604-08459, role PI, 06/01/17 Â 05/31/21, (13) NMSS, PA-1604-08459, role PI, 06/01/17 Â 05/31/21, (14) King Abdulaziz City for Science & Technology, 117427, role PI, 06/01/17 Â 05/31/18, (15) NIH, 5R01DK108894-01, role Co-I, 02/01/17 Â 01/31/22,
(1) Harvard Medical School, Diversity and Community Partnership Faculty Fellowship, Role PI, 2010-2012, (2) BADERC, Pilot and Feasibility Award (Quintana), Role PI, 2010-2012
(1) NMSS, RG4111A1/1, Role PI, 2009-2012, (2) NMSS, RG4048A11, Role Research Associate, 2008-2011
AnTolRx
NONE
NONE
NONE
NONE
NONE
- From the Ann Romney Center for Neurologic Diseases (V.R., J.E.K., Z.L., E.T., M.C.T., C.-C.C., K.A.d.L., D.M.B., F.J.Q.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Klinikum rechts der Isar (V.R.), Department of Neurology, Technical University of Munich, Germany; Department of Neurology (V.R.), University Hospital Erlangen, Friedrich–Alexander University Erlangen–Nürnberg, Germany; Ayala Pharmaceuticals (J.K.), Rehovot, Israel; and Broad Institute of MIT and Harvard (F.J.Q.), Cambridge, MA.
- Correspondence
Dr. Quintana fquintana{at}rics.bwh.harvard.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Dynamic regulation of serum aryl hydrocarbon receptor agonists in MSVeit Rothhammer, Davis M. Borucki, Maria Isabel Garcia Sanchez et al.Neurology: Neuroimmunology & Neuroinflammation, June 16, 2017 -
Article
Oligodendrocyte ARNT2 expression is altered in models of MSPierre Becquart, Jake Johnston, Carles Vilariño-Güell et al.Neurology: Neuroimmunology & Neuroinflammation, May 21, 2020 -
Article
Critical role for prokineticin 2 in CNS autoimmunityMhamad Abou-Hamdan, Massimo Costanza, Elena Fontana et al.Neurology - Neuroimmunology Neuroinflammation, April 09, 2015 -
Article
Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MSThanos Tsaktanis, Tobias Beyer, Lucy Nirschl et al.Neurology: Neuroimmunology & Neuroinflammation, December 24, 2020